骨肉瘤组织VEGF与CD15的表达及其相关性研究  

Expression and association of VEGF and CD15 in osteosarcoma tissues

作　　者：杨军[1] 顾始伟[1] 张钦明[1] 

机构地区：[1]中国医科大学附属盛京医院脊柱创伤骨科,辽宁沈阳110004

出　　处：《中华肿瘤防治杂志》2011年第17期1378-1381,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨血管内皮细胞生长因子(VEGF)与细胞黏附分子CD15的表达及其与骨肉瘤的分级、转移和预后的关系。方法:免疫组化法检测38例骨肉瘤组织中VEGF和CD15的表达水平,并结合骨肉瘤的生物学行为及临床随访资料进行分析和综合评价。同时设10例骨软骨瘤作为阴性对照组。结果:骨软骨瘤组织中VEGF的阳性率为20.0%(2/10),CD15呈阴性表达。骨肉瘤组织中VEGF和CD15的表达率分别是76.3%(29/38)和65.8%(25/38)。VEGF与病理分级无关,P=0.391;CD15与病理分级有关,P=0.028。VEGF和CD15都与转移有关,r值分别为0.612 2、0.695 7。CD15和(或)VEGF阳性表达者5年生存率均明显低于阴性表达组,P=0.001。CD15和VEGF均阳性表达者生存率最低,而二者均阴性表达者生存率最高。结论:VEGF和CD15是骨肉瘤转移和预后不良的重要生物学指标,两者在骨肉瘤的发生和转移方面具有相互协同作用。临床上,检测VEGF和CD15的表达对骨肉瘤患者的预后有重要价值。OBJECTIVE：To study the association of vascular endothelial growth factor（VEGF） and the expression of cell adhesion molecules CD15 in osteosarcoma grade,metastasis and prognosis.METHODS： Use immunohistochemical method to detect 38 cases of osteosarcoma in the expression of VEGF and CD15,combined with the biological behavior of osteosarcoma and clinical follow-up data for analysis and evaluation.At the same time with 10 cases of benign tumor of bone cartilage as a negative control.RESULTS： VEGF positive rate in benign tumor of bone was 20.0%（2/10）,and CD15 was negative.VEGF in osteosarcoma and CD15 expression rates were 76.3%（29/38） and 65.8%（25/38）.Expression of VEGF was not associated with tumor grade（P=0.391）,but CD15 was（P=0.028）.Both VEGF and CD15 were related to osteosarcoma metastasis（r= 0.612 2,r=0.695 7）.The 5-year survival rate of patients with VEGF and（or） CD15 positive expression was significantly lower than those with negative expression（P=0.001）.CONCLUSIONS： VEGF and CD15 are important biological indicators of metastasis and poor prognosis,both have a synergistic effect in the occurrence and metastasis of osteosarcoma.Clinically,detection of expression of VEGF and CD15 for the prognosis of osteosarcoma patients have significant value.

关 键 词：血管内皮细胞生长因子 细胞黏附分子 骨肉瘤 免疫组织化学 

分 类 号：R738[医药卫生—肿瘤]